Forget anything I said about Nicosan II, that was a mistake on my part to even bring up, it's a secondary plan should the license for Nicosan be taken away.
With that said, you're absolutely right in everything you've said, in my opinion. As I stated in a recent post, the Nicosan license in the US and EU will stay with Xechem International, even if they sell Xechem Nigeria. So the orphan drug approvals in each area stay with Xechem International. The plan then would be to move on getting approvals for Nicosan and market it. It's a long process...
I apologize for my earlier mistake of mentioning Nicosan II, but it is plan B should the Nicosan license be revoked.
You're right about the passion, the lack of it in current management and the abundance of it in former management. It's important and it has helped with support or lack thereof.
News 
Market Data 
Discover 
